Replies to post #595498 on NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

I might voice a possible concern. As this thread seems to assume that Oncovir on its own is going nowhere with the patent due to expire shortly, but would be worth alot in the hands of NWBO as part of the dcvax platform. It seems to me that with LP seemingly demanding a top dollar from BP (whichever one) the thing to do for a BP is to acquire Oncovir at a multiple of its current value, but this would still be a dirt cheap entree to NWBO for a necessary ingredient for DCVAX. Right now would the time to do this as the BP could easily outbid NWBO in its bid for Oncovir at this time - this may not be true further down the road..

[dstock07734]

Thanks, meirluc.

As ATL mentioned before, I was even thinking that DCVax-L gets approval along with poly-iclc. Maybe that's the reason Salazar hired a professional reviewer from FDA.
https://www.linkedin.com/in/vmool/

If poly-iclc approved working as maturation and excitation agent in vivo, over 50% percent GBM patients could be saved. It is a huge deal. I read the paper about poly-iclc used as maturation and excitation agent in vivo. I assume there is a possibility poly-iclc is approved along with DCVax-L.

https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02017-2